• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

免疫功能低下的癌症患者中的良性 COVID-19 - 一对夫妇的病例。

Benign COVID-19 in an immunocompromised cancer patient -  the case of a married couple.

机构信息

Family Medicine, Unità Sanitaria Locale del Servizio Sanitario Regionale Emilia-Romagna, Modena, Italy.

Radiology, Ospedale di Sassuolo (Prov. Modena), Italy.

出版信息

Swiss Med Wkly. 2020 Apr 11;150:w20246. doi: 10.4414/smw.2020.20246. eCollection 2020 Apr 6.

DOI:10.4414/smw.2020.20246
PMID:32277836
Abstract

Respiratory failure in COVID-19 is a common feature in fatal cases and has been considered as a failure of the immune system to control the virus. Here we report the case of COVID-19 affecting an immunocompromised women and her presumably immunocompetent spouse. A married couple (age 60 years) was simultaneously admitted to the emergency department on 10 March 2020 because of dyspnoea and fever, consistent with COVID-19. The wife (patient 1) was partially immunocompromised as a consequence of a recently started chemotherapy with fulvestrant and abemaciclid for recurring breast cancer, her husband (patient 2) had been healthy except for a history of controlled arterial hypertension. Both patients were treated with darunavir/cobicistat and hydroxychloroquine. The clinical course of the immunocompromised partner was benign, without need of intensive care. She was able to leave the hospital on day 6 after admission. In contrast, her husband needed intensive care and his recovery was slow, although eventually successful too. These findings suggest that the course of COVID-19 is not necessarily ominous in the presence of a compromised immune response and tend to reinforce the emerging therapeutic concepts of a controlled mitigation of the immune cascade following SARS CoV-2 infection.

摘要

新型冠状病毒病(COVID-19)导致的呼吸衰竭是死亡病例的常见特征,被认为是免疫系统未能控制病毒所致。在此,我们报告了一例 COVID-19 影响免疫功能低下的女性及其可能免疫功能正常的配偶的病例。一对 60 岁的已婚夫妇于 2020 年 3 月 10 日因呼吸困难和发热同时被收入急诊科,符合 COVID-19 的诊断。妻子(患者 1)因最近开始使用氟维司群和阿比昔利德化疗治疗复发性乳腺癌而部分免疫功能低下,其丈夫(患者 2)除了有控制良好的高血压病史外,身体一直健康。这两位患者均接受了达芦那韦/考比司他和羟氯喹治疗。免疫功能低下者的临床病程良性,无需重症监护。她在入院后第 6 天就可以出院了。相比之下,她的丈夫需要重症监护,而且恢复缓慢,但最终也成功康复了。这些发现表明,在免疫应答受损的情况下,COVID-19 的病程不一定凶险,这也倾向于强化 SARS-CoV-2 感染后免疫级联反应受到控制的治疗新概念。

相似文献

1
Benign COVID-19 in an immunocompromised cancer patient -  the case of a married couple.免疫功能低下的癌症患者中的良性 COVID-19 - 一对夫妇的病例。
Swiss Med Wkly. 2020 Apr 11;150:w20246. doi: 10.4414/smw.2020.20246. eCollection 2020 Apr 6.
2
Threatening drug-drug interaction in a kidney transplant patient with coronavirus disease 2019 (COVID-19).一名2019冠状病毒病(COVID-19)肾移植患者存在危及生命的药物相互作用。
Transpl Infect Dis. 2020 Aug;22(4):e13286. doi: 10.1111/tid.13286. Epub 2020 Jul 14.
3
Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).新型冠状病毒肺炎 2019 年在癌症患者中的情况。一个西方国家(意大利)首批 25 例癌症患者的报告。
Future Oncol. 2020 Jul;16(20):1425-1432. doi: 10.2217/fon-2020-0369. Epub 2020 May 14.
4
Effectiveness of Streptococcus Pneumoniae Urinary Antigen Testing in Decreasing Mortality of COVID-19 Co-Infected Patients: A Clinical Investigation.肺炎链球菌尿抗原检测对降低 COVID-19 合并感染患者死亡率的有效性:一项临床研究。
Medicina (Kaunas). 2020 Oct 29;56(11):572. doi: 10.3390/medicina56110572.
5
Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection.使用达芦那韦-考比司他作为重症新型冠状病毒肺炎患者的一种治疗选择。
Yonsei Med J. 2020 Sep;61(9):826-830. doi: 10.3349/ymj.2020.61.9.826.
6
A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19: A structured summary of a study protocol for a randomised controlled trial.一项评估法匹拉韦和羟氯喹联合治疗中重度 COVID-19 住院成人的疗效和安全性的随机对照研究:研究方案的结构化总结。
Trials. 2020 Oct 31;21(1):904. doi: 10.1186/s13063-020-04825-x.
7
Outpatient treatment of COVID-19 with steroids in the phase of mild pneumonia without the need for admission as an opportunity to modify the course of the disease: A structured summary of a randomised controlled trial.轻症肺炎患者无需住院的情况下使用类固醇进行 COVID-19 门诊治疗作为改变疾病进程的机会:一项随机对照试验的结构化总结。
Trials. 2020 Jul 9;21(1):632. doi: 10.1186/s13063-020-04575-w.
8
Norwegian Coronavirus Disease 2019 (NO COVID-19) Pragmatic Open label Study to assess early use of hydroxychloroquine sulphate in moderately severe hospitalised patients with coronavirus disease 2019: A structured summary of a study protocol for a randomised controlled trial.挪威 2019 年冠状病毒病(NO COVID-19)实用开放性标签研究,评估硫酸羟氯喹在 2019 年冠状病毒病中度重症住院患者中的早期使用:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jun 5;21(1):485. doi: 10.1186/s13063-020-04420-0.
9
Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.阿奇霉素和羟氯喹对新冠肺炎住院患者的前瞻性预防(ProPAC-COVID):一项随机对照试验研究方案的结构化总结
Trials. 2020 Jun 10;21(1):513. doi: 10.1186/s13063-020-04409-9.
10
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.SARS-CoV-2 依维莫司纳瓦拉-ISGlobal 试验(SAINT)评估依维莫司在症状出现后 48 小时内降低低危、非重症 COVID-19 患者 COVID-19 传播风险的潜力:一项随机对照试验方案的研究方案结构化总结。
Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.

引用本文的文献

1
Impact of the COVID-19 Pandemic on the Treatment of Cancer Patients at a Hospital in Peru.COVID-19 大流行对秘鲁一家医院癌症患者治疗的影响。
Cancer Control. 2024 Jan-Dec;31:10732748241276616. doi: 10.1177/10732748241276616.
2
Early predictors of intensive care unit admission among COVID-19 patients in Qatar.卡塔尔 COVID-19 患者入住重症监护病房的早期预测指标。
Front Public Health. 2024 Mar 20;12:1278046. doi: 10.3389/fpubh.2024.1278046. eCollection 2024.
3
Coexistence of malignancy and tuberculosis: is it double disease or double hit related to COVID-19? - Experience from a tertiary care center.
恶性肿瘤与结核病并存:是双重疾病还是与新冠病毒相关的双重打击?——来自三级医疗中心的经验
Int J Clin Exp Pathol. 2023 Jan 15;16(1):1-7. eCollection 2023.
4
COVID-19 vaccination in patients with cancer: Opportunities and challenges.癌症患者的新冠病毒疫苗接种:机遇与挑战。
Front Oncol. 2022 Nov 8;12:1029325. doi: 10.3389/fonc.2022.1029325. eCollection 2022.
5
The impact of cancer on the severity of disease in patients affected with COVID-19: an umbrella review and meta-meta-analysis of systematic reviews and meta-analyses involving 1,064,476 participants.癌症对合并 COVID-19 患者疾病严重程度的影响:一项包含 1,064,476 名参与者的系统评价和荟萃分析的伞状评价和荟萃荟萃分析。
Clin Exp Med. 2023 Oct;23(6):2221-2229. doi: 10.1007/s10238-022-00911-3. Epub 2022 Oct 7.
6
Small Molecules Targeting SARS-CoV-2 Spike Glycoprotein Receptor-Binding Domain.靶向严重急性呼吸综合征冠状病毒2刺突糖蛋白受体结合域的小分子
ACS Omega. 2022 Aug 9;7(33):28779-28789. doi: 10.1021/acsomega.2c00844. eCollection 2022 Aug 23.
7
Effects of SARS-CoV-2 infections in patients with cancer on mortality, ICU admission and incidence: a systematic review with meta-analysis involving 709,908 participants and 31,732 cancer patients.SARS-CoV-2 感染对癌症患者死亡率、入住 ICU 率和发病率的影响:一项涉及 709908 名参与者和 31732 例癌症患者的系统评价和荟萃分析。
J Cancer Res Clin Oncol. 2023 Jul;149(7):2915-2928. doi: 10.1007/s00432-022-04191-y. Epub 2022 Jul 13.
8
Novel approaches for COVID-19 diagnosis and treatment: a nonsystematic review.新型冠状病毒肺炎诊断与治疗的新方法:一项非系统性综述
Turk J Biol. 2021 Aug 30;45(4):358-371. doi: 10.3906/biy-2105-45. eCollection 2021.
9
Hydroxychloroquine: A review of its safety and efficacy in COVID-19.羟氯喹:关于其在2019冠状病毒病中的安全性和疗效的综述
J Family Med Prim Care. 2021 Mar;10(3):1124-1133. doi: 10.4103/jfmpc.jfmpc_1961_20. Epub 2021 Apr 8.
10
Comorbidities and inflammation associated with ovarian cancer and its influence on SARS-CoV-2 infection.与卵巢癌相关的合并症和炎症及其对 SARS-CoV-2 感染的影响。
J Ovarian Res. 2021 Feb 25;14(1):39. doi: 10.1186/s13048-021-00787-z.